Gavi and the post 2015 development agenda

in page functions

Gavi has called for an ambitious vaccine indicator to help monitor the implementation of the sustainable development goals.

GAVI_2012_Sala Lewis_2_Tanzania.jpg

Photo credit: Gavi/2012/Sala Lewis.

With new sustainable development goals (SDGs) set for global endorsement at the United Nations General Assembly in September 2015, attention is turning to how to monitor the goals.

Gavi has called on the Inter-Agency Expert Group (IAEG-SDGs), set up by the UN to develop a global indicator framework, to include a vaccine-specific indicator. This would measure progress against the following objective:

“Reach and sustain 90% national coverage and 80% in every district with all vaccines in national programmes.”

The added value of this immunisation indicator is that it is responsive to scientific and development advances by measuring coverage of all vaccines in national programmes. It very much aligns with the intent of the SDGs to have relevance at the national level, across all countries, and be able to be meaningfully aggregated. 

Gavi CEO Dr Seth Berkley

Every year 1.5 million children under five lose their lives to vaccine preventable diseases. However, 19 million infants worldwide still miss out on the basic package of vaccines.

A vaccine-specific indicator would recognise the role of vaccination in ensuring every child has a healthy start to their lives. It is also suitable for tracking overall progress of the SDGs because:

  • Immunisation is a critical and practical health coverage measure.
  • Every nation measures immunisation and national data can be aggregated at the global level.
  • The proposed indicator will gauge success across a number of areas including the strength of health systems, equity, human rights and child survival.

The proposed indicator would not require additional monitoring at country level. It would build on a pre-existing indicator already agreed by all UN member states through the Global Vaccine Action Plan (GVAP), which was endorsed at the 2012 World Health Assembly.

Read more about the IAEG-SDGs and the process put in place to develop the monitoring framework.

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here